DMSI.US Dermisonics Inc
- Market cap
- USD 1.92K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2007.
Is DMSI.US undervalued?
Graham numberThe Graham number of Dermisonics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dermisonics Inc fundamental analysis
No fundamental analysis for Dermisonics Inc yet.
Dermisonics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dermisonics Inc
Dermisonics, Inc. manufactures ultrasonic transdermal drug-delivery technologies and equipment. It primarily focuses on the development, testing, and commercialization of its active transdermal patch, called the U-Strip, that has been designed to facilitate the needle-free delivery of drugs with large molecular structures, such as Insulin into the bloodstream. The company was formerly known as Second Stage Ventures, Inc. and changed its name to Dermisonics, Inc. in October 2…
Full company profileDermisonics Inc financial statements
2007 annualized: Fiscal year 2007 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2007, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dermisonics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2003 | 2004 | 2005 | 2006 | 2007 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -55.4K | -3.84M | -5.73M | -4.11M | -1.34M |
| Net Income | -82.5K | -3.99M | -6.96M | -5.08M | -28.3M |
| Balance Sheet | |||||
| Total Assets | 35.9K | 19.4M | 19.9M | 20.1M | 35.2K |
| Total Liabilities | 8.64K | 3.33M | 4.15M | 4.47M | 4.24M |
| Shareholders' Equity | 27.3K | 16.1M | 15.8M | 15.6M | -4.20M |
| Cash & Short-term Investments | 3.40K | - | 357K | 126K | 22.8K |
| Cash Flow | |||||
| Operating Cash Flow | -74.7K | -62.9K | -1.22M | -1.30M | -359K |
| Capital Expenditure | 3.02K | 3.02K | 3.02K | 3.02K | 0.00 |
| Ratios | |||||
| ROE | -302.5% | -24.8% | -44.1% | -32.6% | - |
| ROA | -229.7% | -20.5% | -34.9% | -25.3% | -80,254.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Dermisonics Inc dividends
Dermisonics Inc has not paid dividends in the last 4 fiscal years.
Last stock split: 3:2 on Jan 19, 2005.
Who owns Dermisonics Inc
Ownership data of Dermisonics Inc is not available yet.
Dermisonics Inc company profile
- Company name
- Dermisonics Inc
- Ticker
- DMSI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- September
- Address
- 2 Park Plaza, Irvine, CA, United States, 92614
- Phone
- 949-733-1101
- Website
- -
About Dermisonics Inc
Dermisonics, Inc. manufactures ultrasonic transdermal drug-delivery technologies and equipment. It primarily focuses on the development, testing, and commercialization of its active transdermal patch, called the U-Strip, that has been designed to facilitate the needle-free delivery of drugs with large molecular structures, such as Insulin into the bloodstream. The company was formerly known as Second Stage Ventures, Inc. and changed its name to Dermisonics, Inc. in October 2004. Dermisonics, Inc. was founded in 2000 and is based in Irvine, California.
Dermisonics Inc management
1- Mr. Bruce H. Haglund Esq., J.D.Executive Chairman, Acting Principal Exec.,Financial & Accounting Officer · born 1952